Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
DEXCOM INC
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-78.6% vs price
Base Case (Median)
-56.0% vs price
Bull Case (75th pct.)
-22.6% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $16.01 | -81.2% | High (40%) |
| PE Comparable | $56.59 | -33.7% | Medium (25%) |
| Growth Trajectory DCF | $103.81 | 21.6% | Medium (20%) |
| Graham Number | $20.18 | -76.4% | Medium (40%) |
| EV/EBITDA | $37.54 | -56.0% | Medium (20%) |
| EV/FCF | $75.52 | -11.5% | Medium (20%) |
| Earnings Power Value | $16.37 | -80.8% | Medium (50%) |
Based on 7 out of 7 methods, DXCM appears overvalued at the current price of $85.36. The base case fair value of $37.54 implies 56.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.